CEACAM5 and neoplasm: Therefore, during this initial critical period up until the first interval assessment scan, having a convenient and minimally invasive biomarker that can reliably monitor tumor response to immunotherapy can be of immense benefit to the physician while easing patient anxiety, particularly in the absence of high CEA levels to begin with.